Pharsight

Abilify Asimtufii patents expiration

ABILIFY ASIMTUFII's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399469 OTSUKA Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Jun, 2025

(1 year, 1 month from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759351 OTSUKA Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US8338428 OTSUKA Methods for administering aripiprazole
Aug, 2023

(9 months ago)

US8338427 OTSUKA Methods for administering aripiprazole
Mar, 2025

(9 months from now)

US10517951 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)

US11097007 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)

US11638757 OTSUKA Injectable preparation
Apr, 2033

(8 years from now)

Abilify Asimtufii is owned by Otsuka.

Abilify Asimtufii contains Aripiprazole.

Abilify Asimtufii has a total of 7 drug patents out of which 2 drug patents have expired.

Expired drug patents of Abilify Asimtufii are:

  • US8759351
  • US8338428

Abilify Asimtufii was authorised for market use on 27 April, 2023.

Abilify Asimtufii is available in suspension, extended release;intramuscular dosage forms.

Abilify Asimtufii can be used as maintenance monotherapy treatment of bipolar i disorder, treatment of schizophrenia, use of aripiprazole in extended release injectable suspension.

The generics of Abilify Asimtufii are possible to be released after 23 April, 2033.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ARIPIPRAZOLE ingredient

Market Authorisation Date: 27 April, 2023

Treatment: Use of aripiprazole in extended release injectable suspension; Maintenance monotherapy treatment of bipolar i disorder; Treatment of schizophrenia

Dosage: SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage

ABILIFY ASIMTUFII family patents

Family Patents